Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term dexamethasone. Found 8 abstracts

Shah JJ, Kaufman JL, Zonder JA, Cohen AD, Bensinger WI, Hilder BW, Rush SA, Walker DH, Tunquist BJ, Litwiler KS, Ptaszynski M, Orlowski RZ, Lonial S. A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma. Cancer. 2017 Dec;123(23):4617-30.   PMCID: PMC5856158
Pro B, Perini GF. Brentuximab vedotin in Hodgkin's lymphoma. Expert Opinion on Biological Therapy. 2012 Oct;12(10):1415-21.   PMCID: Not NIH Funded
Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Huff CA, Kassim A, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F. Multiple Myeloma. Journal of the National Comprehensive Cancer Network. 2011 Oct;9(10):1146-83.   PMCID: not NIH funded
Brem SS, Bierman PJ, Brem H, Butowski N, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Junck L, Linette GP, Loeffler JS, Maor MH, Michael M, Moots PL, Morrison T, Mrugala M, Nabors LB, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK, Vrionis FD, Wen PY. Central Nervous System Cancers. Journal of the National Comprehensive Cancer Network. 2011 Apr;9(4):352-400.   PMCID: not NIH funded
Giralt SA, Mangan KF, Maziarz RT, Bubalo JS, Beveridge R, Hurd DD, Mendoza FL, Rubenstein EB, DeGroot TJ, Schuster MW. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Annals of Oncology. 2011 Apr;22(4):939-46.   PMCID: not NIH funded
Smith MR, Joshi I, Jin F, Obasaju C. Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice. BMC cancer. 2005 Aug 18;5:Art.
Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-Lopez AJ, White CA. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood. 2002 Jun 15;99(12):4336-42.
Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Annals of Oncology. 1997 Jun;8(6):611-4.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term dexamethasone

dexamethasone chemotherapy stem-cell transplantation NCCN Guidelines combination NCCN Clinical Practice Guidelines multiple myeloma rituximab moderately emetogenic glioblastoma i-131 nausea spindle poles double-blind monoclonal-antibody positron-emission-tomography phase-ii trial cisplatin spinal-cord compression quality-of-life 2-chlorodeoxyadenosine radiotherapy plus concomitant ondansetron filanesib kinesin maximum tolerated dose C-reactive protein randomized controlled-trial hypersensitivity brain tumor astrocytoma disease taxol single-agent mouse model brentuximab vedotin antibody-drug conjugate-CD30-Hodgkin's lymphoma-MMAE-SGN-35 idec-c2b8 high-dose therapy brain metastases brain radiation-therapy anaplastic astrocytoma 2004 nseca r-cancer res-v64-p1546 cell lung-carcinoma angiogenesis cytotoxic drugs myelodysplastic syndrome immunomodulatory drugs donor lymphocyte infusions PTEN (JNCCN 2011 Waldenstrom's monoclonal protein regimen hematologic malignancies medulloblastoma gemcitabine average-risk medulloblastoma pegylated liposomal doxorubicin progression bone-marrow transplantation 2011 carthy p-haematologica-v96-ps23 phase-iii s-phase 9:352-400) consensus conference doxorubicin newly-diagnosed myeloma survival phase-ii novel therapies term follow-up cytogenetics refractory high-dose melphalan supportive therapies irinotecan induced emesis rates myeloma paclitaxel gamma-knife surgery multicenter sgn-30 spinal tumors thalidomide plus temozolomide palonosetron recurrent malignant glioma bevacizumab bisphosphonates high response plus proteasome inhibitor primary amyloidosis 2009 carthy pl-blood-v114 chemotherapy-induced nausea high-dose pharmacokinetics stem cell transplant cremophor salvage therapy 5-ht3 receptor
Last updated on Sunday, July 05, 2020